{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:05:19Z","timestamp":1751083519445,"version":"3.41.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["P50HD103537"],"award-info":[{"award-number":["P50HD103537"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001819","name":"Rettsyndrome.org","doi-asserted-by":"publisher","award":["3906"],"award-info":[{"award-number":["3906"]}],"id":[{"id":"10.13039\/100001819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013017","name":"Vanderbilt University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["MH124671"],"award-info":[{"award-number":["MH124671"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jpet.2025.103602","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:14:42Z","timestamp":1746771282000},"page":"103602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potentiation of group III metabotropic glutamate receptors positively affects neurophysiological features in a mouse model of Rett syndrome"],"prefix":"10.1016","volume":"392","author":[{"given":"Hong-Wei","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8187-8690","authenticated-orcid":false,"given":"Mac J.","family":"Meadows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Zagol-Ikapitte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Boutaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerri M.","family":"Rook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5628-5872","authenticated-orcid":false,"given":"Jeffrey L.","family":"Neul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen M.","family":"Niswender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103602_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1165\/rcmb.2013-0372OC","article-title":"Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome","volume":"50","author":"Abdala","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jpet.2025.103602_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13072-018-0219-8","article-title":"Perturbed maintenance of transcriptional repression on the inactive X-chromosome in the mouse brain after Xist deletion","volume":"11","author":"Adrianse","year":"2018","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.jpet.2025.103602_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.jpet.2025.103602_bib4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.neuropharm.2007.12.009","article-title":"Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated","volume":"54","author":"Ayala","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpet.2025.103602_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fpsyt.2012.00034","article-title":"Rett syndrome: genes, synapses, circuits, and therapeutics","volume":"3","author":"Banerjee","year":"2012","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jpet.2025.103602_bib6","doi-asserted-by":"crossref","first-page":"E668","DOI":"10.1073\/pnas.1715124115","article-title":"A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders","volume":"115","author":"Carrette","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jpet.2025.103602_bib7","doi-asserted-by":"crossref","first-page":"9941","DOI":"10.1073\/pnas.1311685111","article-title":"Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome","volume":"111","author":"Castro","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jpet.2025.103602_bib8","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1021\/acschemneuro.2c00113","article-title":"Optimized administration of the M(4) PAM VU0467154 demonstrates broad efficacy, but limited effective concentrations in Mecp2(+\/\u2013) mice","volume":"13","author":"Cikowski","year":"2022","journal-title":"ACS Chem Neurosci"},{"year":"2014","series-title":"Analyzing Neural Time Series Data: Theory and Practice","author":"Cohen","key":"10.1016\/j.jpet.2025.103602_bib9"},{"key":"10.1016\/j.jpet.2025.103602_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12739","article-title":"Safety and efficacy of genetic MECP2 supplementation in the R294X mouse model of Rett syndrome","volume":"21","author":"Collins","year":"2022","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.jpet.2025.103602_bib11","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2147\/NDT.S371483","article-title":"Rett syndrome and MECP2 duplication syndrome: disorders of MeCP2 dosage","volume":"18","author":"Collins","year":"2022","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jpet.2025.103602_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jmedgenet-2013-102113","article-title":"Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome","volume":"51","author":"Cuddapah","year":"2014","journal-title":"J Med Genet"},{"key":"10.1016\/j.jpet.2025.103602_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105083","article-title":"Detection of neurophysiological features in female R255X MeCP2 mutation mice","volume":"145","author":"Dong","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jpet.2025.103602_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00384","article-title":"Potentiation of the muscarinic acetylcholine receptor 1 modulates neurophysiological features in a mouse model of Rett syndrome","volume":"21","author":"Dong","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jpet.2025.103602_bib15","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1542\/peds.2013-0819","article-title":"Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis","volume":"133","author":"Doshi-Velez","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpet.2025.103602_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2020-000731","article-title":"Multisystem comorbidities in classic Rett syndrome: a scoping review","volume":"4","author":"Fu","year":"2020","journal-title":"BMJ Paediatr Open"},{"key":"10.1016\/j.jpet.2025.103602_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2020-000717","article-title":"Consensus guidelines on managing Rett syndrome across the lifespan","volume":"4","author":"Fu","year":"2020","journal-title":"BMJ Paediatr Open"},{"key":"10.1016\/j.jpet.2025.103602_bib18","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1021\/acs.jmedchem.2c00192","article-title":"Development of VU6019650: a potent, highly selective, and systemically active orthosteric antagonist of the M(5) muscarinic acetylcholine receptor for the treatment of opioid use disorder","volume":"65","author":"Garrison","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpet.2025.103602_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nn.2997","article-title":"Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses","volume":"15","author":"Goffin","year":"2011","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jpet.2025.103602_bib20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nn.3710","article-title":"Cellular origins of auditory event-related potential deficits in Rett syndrome","volume":"17","author":"Goffin","year":"2014","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jpet.2025.103602_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai7459","article-title":"mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome","volume":"9","author":"Gogliotti","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jpet.2025.103602_bib22","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/hmg\/ddw074","article-title":"mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome","volume":"25","author":"Gogliotti","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpet.2025.103602_bib23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.1138389","article-title":"Reversal of neurological defects in a mouse model of Rett syndrome","volume":"315","author":"Guy","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jpet.2025.103602_bib24","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/cn500153z","article-title":"Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7","volume":"5","author":"Jalan-Sakrikar","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.jpet.2025.103602_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11689-022-09455-9","article-title":"Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome","volume":"14","author":"Jonak","year":"2022","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.jpet.2025.103602_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129106","article-title":"Persistent challenges in the development of an mGlu(7) PAM in vivo tool compound: the discovery of VU6046980","volume":"80","author":"Kalbfleisch","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jpet.2025.103602_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1124\/jpet.114.214437","article-title":"Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders","volume":"350","author":"Kalinichev","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103602_bib28","article-title":"Development of trofinetide for the treatment of Rett syndrome: from bench to bedside","volume":"14","author":"Kennedy","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2025.103602_bib29","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1523\/JNEUROSCI.4543-14.2015","article-title":"Activation of metabotropic glutamate receptor 7 is required for induction of long-term potentiation at SC-CA1 synapses in the hippocampus","volume":"35","author":"Klar","year":"2015","journal-title":"J Neurosci"},{"key":"10.1016\/j.jpet.2025.103602_bib30","doi-asserted-by":"crossref","first-page":"13860","DOI":"10.1523\/JNEUROSCI.2159-12.2012","article-title":"Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment","volume":"32","author":"Kron","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.jpet.2025.103602_bib31","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1172\/JCI90967","article-title":"Elevating expression of MeCP2 T158M rescues DNA binding and Rett syndrome-like phenotypes","volume":"127","author":"Lamonica","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jpet.2025.103602_bib32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/hmg\/ddt421","article-title":"Rescue of behavioral and EEG deficits in male and female Mecp2-deficient mice by delayed Mecp2 gene reactivation","volume":"23","author":"Lang","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpet.2025.103602_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/jpet.112.196063","article-title":"A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease","volume":"343","author":"Le Poul","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103602_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nyas.12730","article-title":"Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia","volume":"1344","author":"Light","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jpet.2025.103602_bib35","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/hmg\/ddaa102","article-title":"Pharmacological read-through of R294X Mecp2 in a novel mouse model of Rett syndrome","volume":"29","author":"Merritt","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpet.2025.103602_bib36","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1016\/S0021-9258(19)50280-0","article-title":"Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate","volume":"268","author":"Nakajima","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpet.2025.103602_bib37","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ana.22124","article-title":"Rett syndrome: revised diagnostic criteria and nomenclature","volume":"68","author":"Neul","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpet.2025.103602_bib38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jpet.2025.103602_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jpet.2025.103602_bib40","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1021\/acschemneuro.6b00036","article-title":"Development and antiparkinsonian activity of VU0418506, a selective positive allosteric modulator of metabotropic glutamate receptor 4 homomers without activity at mGlu2\/4 heteromers","volume":"7","author":"Niswender","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.jpet.2025.103602_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1172805","article-title":"Advanced genetic therapies for the treatment of Rett syndrome: state of the art and future perspectives","volume":"17","author":"Palmieri","year":"2023","journal-title":"Front Neurosci"},{"key":"10.1016\/j.jpet.2025.103602_bib42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1021\/acsmedchemlett.8b00426","article-title":"Discovery of VU2957 (Valiglurax): an mGlu(4) positive allosteric modulator evaluated as a preclinical candidate for the treatment of Parkinson\u2019s disease","volume":"10","author":"Panarese","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpet.2025.103602_bib43","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dmcn.15383","article-title":"State-of-the-art therapies for Rett syndrome","volume":"65","author":"Panayotis","year":"2023","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.jpet.2025.103602_bib44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.biopsych.2015.08.018","article-title":"Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves Rett syndrome phenotype","volume":"79","author":"Patrizi","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpet.2025.103602_bib45","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-024-01106-y","article-title":"Rett syndrome: the emerging landscape of treatment strategies","volume":"38","author":"Percy","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpet.2025.103602_bib46","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/hmg\/ddt111","article-title":"Insulinotropic treatments exacerbate metabolic syndrome in mice lacking MeCP2 function","volume":"22","author":"Pitcher","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpet.2025.103602_bib47","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1073\/pnas.1803792115","article-title":"Pharmacological reactivation of inactive X-linked Mecp2 in cerebral cortical neurons of living mice","volume":"115","author":"Przanowski","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jpet.2025.103602_bib48","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1021\/acsmedchemlett.0c00432","article-title":"Discovery of VU6027459: a first-in-class selective and CNS penetrant mGlu7 positive allosteric modulator tool compound","volume":"11","author":"Reed","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jpet.2025.103602_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s11689-019-9275-z","article-title":"Electroencephalographic spectral power as a marker of cortical function and disease severity in girls with Rett syndrome","volume":"11","author":"Roche","year":"2019","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.jpet.2025.103602_bib50","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ana.26029","article-title":"Multisite study of evoked potentials in Rett syndrome","volume":"89","author":"Saby","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpet.2025.103602_bib51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ana.26948","article-title":"Electroencephalographic correlates of clinical severity in the natural history study of RTT and related disorders","volume":"96","author":"Saby","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpet.2025.103602_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s11689-023-09479-9","article-title":"Comparison of evoked potentials across four related developmental encephalopathies","volume":"15","author":"Saby","year":"2023","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.jpet.2025.103602_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fnint.2020.00030","article-title":"Evoked potentials and EEG analysis in Rett syndrome and related developmental encephalopathies: towards a biomarker for translational research","volume":"14","author":"Saby","year":"2020","journal-title":"Front Integr Neurosci"},{"key":"10.1016\/j.jpet.2025.103602_bib54","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1007\/s13311-022-01254-3","article-title":"Clinical and preclinical evidence for M1 muscarinic acetylcholine receptor potentiation as a therapeutic approach for Rett syndrome","volume":"19","author":"Smith","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jpet.2025.103602_bib55","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1073\/pnas.1621356114","article-title":"Screen for reactivation of MeCP2 on the inactive X chromosome identifies the BMP\/TGF-beta superfamily as a regulator of XIST expression","volume":"114","author":"Sripathy","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpet.2025.103602_bib56","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/cells9010240","article-title":"The expanding therapeutic potential of neuronal KCC2","volume":"9","author":"Tang","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jpet.2025.103602_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau0164","article-title":"Pharmacological enhancement of KCC2 gene expression exerts therapeutic effects on human Rett syndrome neurons and Mecp2 mutant mice","volume":"11","author":"Tang","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jpet.2025.103602_bib58","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/brain\/aww302","article-title":"Longitudinal course of epilepsy in Rett syndrome and related disorders","volume":"140","author":"Tarquinio","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.jpet.2025.103602_bib59","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.braindev.2018.03.010","article-title":"The course of awake breathing disturbances across the lifespan in Rett syndrome","volume":"40","author":"Tarquinio","year":"2018","journal-title":"Brain Dev"},{"key":"10.1016\/j.jpet.2025.103602_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fncir.2016.00031","article-title":"Phasic and tonic mGlu7 receptor activity modulates the thalamocortical network","volume":"10","author":"Tassin","year":"2016","journal-title":"Front Neural Circuits"},{"key":"10.1016\/j.jpet.2025.103602_bib61","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1073\/pnas.0812394106","article-title":"Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice","volume":"106","author":"Tropea","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jpet.2025.103602_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109022","article-title":"Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome","volume":"209","author":"Vermudez","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpet.2025.103602_bib63","doi-asserted-by":"crossref","first-page":"13257","DOI":"10.1523\/JNEUROSCI.2332-14.2015","article-title":"Age-related changes in 1\/f neural electrophysiological noise","volume":"35","author":"Voytek","year":"2015","journal-title":"J Neurosci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:17:28Z","timestamp":1751019448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0022356525398150"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103602","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentiation of group III metabotropic glutamate receptors positively affects neurophysiological features in a mouse model of Rett syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103602"}}